These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3592 related articles for article (PubMed ID: 7529086)

  • 1. Leukocyte-induced angiogenesis and subcutaneous growth of B16 melanoma.
    Gutman M; Singh RK; Yoon S; Xie K; Bucana CD; Fidler IJ
    Cancer Biother; 1994; 9(2):163-70. PubMed ID: 7529086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice.
    Yang HM; Reisfeld RA
    Proc Natl Acad Sci U S A; 1988 Feb; 85(4):1189-93. PubMed ID: 3422487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antioxidant defenses in a B16 melanoma line resistant to doxorubicin: an in vivo study.
    Crescimanno M; Armata MG; Florena AM; Leonardi V; Rausa L; D'Alessandro N
    Anticancer Drugs; 1991 Oct; 2(5):481-6. PubMed ID: 1687113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bovine lactoferrin and Lactoferricin inhibit tumor metastasis in mice.
    Yoo YC; Watanabe S; Watanabe R; Hata K; Shimazaki K; Azuma I
    Adv Exp Med Biol; 1998; 443():285-91. PubMed ID: 9781371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effect of Korean mistletoe (Viscum album coloratum) extract on tumour angiogenesis and metastasis of haematogenous and non-haematogenous tumour cells in mice.
    Yoon TJ; Yoo YC; Choi OB; Do MS; Kang TB; Lee SW; Azuma I; Kim JB
    Cancer Lett; 1995 Oct; 97(1):83-91. PubMed ID: 7585483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin.
    Pastorino F; Mumbengegwi DR; Ribatti D; Ponzoni M; Allen TM
    J Control Release; 2008 Feb; 126(1):85-94. PubMed ID: 18166243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of tumor-induced angiogenesis by a synthetic lipid A analogue with low endotoxicity, DT-5461.
    Sato K; Yoo YC; Mochizuki M; Saiki I; Takahashi TA; Azuma I
    Jpn J Cancer Res; 1995 Apr; 86(4):374-82. PubMed ID: 7539783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors.
    Eisenthal A; Skornick Y; Merimsky O; Hirsch R; Zakut V; Ron I; Chaitchik S
    Cancer Immunol Immunother; 1993 Sep; 37(4):233-9. PubMed ID: 8348562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and B16 melanoma resistant to doxorubicin.
    Berezhnaya NM; Vinnichuk YD; Belova OB
    Exp Oncol; 2008 Mar; 30(1):52-5. PubMed ID: 18438341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined activity of interleukin-1 alpha or TNF-alpha and doxorubicin on multidrug resistant cell lines: evidence that TNF and DXR have synergistic antitumor and differentiation-inducing effects.
    Borsellino N; Crescimanno M; Flandina C; Flugy A; D'Alessandro N
    Anticancer Res; 1994; 14(6B):2643-8. PubMed ID: 7872695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
    Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
    Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host immunity to mycoplasma antigens introduced into B16 melanoma cells: effect on tumor growth rate and metastasis.
    Stackpole CW; Alterman AL; Fornabaio DM
    Clin Exp Metastasis; 1988; 6(4):271-84. PubMed ID: 3129225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor.
    Funahashi Y; Wakabayashi T; Semba T; Sonoda J; Kitoh K; Yoshimatsu K
    Oncol Res; 1999; 11(7):319-29. PubMed ID: 10757446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.
    DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H
    J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of aging on tumor growth and angiogenesis are tumor-cell dependent.
    Reed MJ; Karres N; Eyman D; Cruz A; Brekken RA; Plymate S
    Int J Cancer; 2007 Feb; 120(4):753-60. PubMed ID: 17131319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo effects of tumor necrosis factor-alpha or flavone acetic acid in combination with doxorubicin on multidrug-resistant B16 melanoma.
    D'Alessandro N; Borsellino N
    Anticancer Drugs; 1996 May; 7(3):281-7. PubMed ID: 8792001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 8-chloro-cyclic adenosine monophosphate on the growth and sensitivity to doxorubicin of multidrug-resistant tumour cell lines.
    Borsellino N; Crescimanno M; Leonardi V; D'Alessandro N
    Pharmacol Res; 1994 Jul; 30(1):81-90. PubMed ID: 7831198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line.
    Yoshiura K; Nishishita T; Nakaoka T; Yamashita N; Yamashita N
    J Exp Clin Cancer Res; 2009 Jan; 28(1):13. PubMed ID: 19183492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo.
    Gutman M; Szold A; Ravid A; Lazauskas T; Merimsky O; Klausner JM
    Anticancer Res; 1996; 16(6B):3673-7. PubMed ID: 9042240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
    Sochanik A; Mitrus I; Smolarczyk R; CichoĊ„ T; Snietura M; Czaja M; Szala S
    Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 180.